eCOA Supports Successful Antianginal Trial

Gilead Sciences’ previous studies of Ranexa (ranolazine) relied on data from exercise treadmill parameters as the primary endpoint. But collecting data in this manner is costly, logistically challenging, and bears questionable clinical relevance — especially at the individual patient level.

Download this case study to learn how Gilead Sciences successfully utilized ERT handhelds to collect regulatory-compliant, patient-driven data in support of the primary efficacy endpoint in a Phase IV study of Ranexa. What worked? What didn’t?

Learn from Gilead’s experience to examine:

  • How data was used to assess efficacy and to support primary trial endpoints
  • Important study device considerations and study endpoint selection
  • How Gilead achieved 98% patient compliance among trial participants

By submitting this form you are consenting to receive digital communications from ERT and you agree to our Privacy Policy and Website Terms of Use.